March 31, 2006 |
Asahi Kasei Pharma Corporation
Eisai Co., Ltd.
|
AKP and Eisai sign sales promotion agreement for Eril™ in China
|
| |
Asahi Kasei Pharma Corp. (AKP) and Eisai China Inc., subsidiary of Eisai Co., Ltd.,
signed an agreement on March 28 giving Eisai China exclusive rights to promote injectable
formulations of
AKP’s vasodilator Eril™ (fasudil hydrochloride) in China.
Under the agreement, effective June 1, 2006, Eisai China will receive a
commission on sales while AKP will continue to be responsible for distribution
of the product to wholesalers in China.
Eril™ is indicated for prevention of cerebral vasospasm and ensuing
cerebral ischemia following surgery for subarachnoid hemorrhage. Eril™
prevents blood vessels from constricting with a new mechanism that inhibits
the protein kinase, which is the last step in the vasoconstriction process.
Eisai is actively concentrating on market development activities in China.
In addition to the sales promotion of its own products including the globally
marketed Aricept*, a drug for the treatment of Alzheimer’s disease,
Eisai is proactively undertaking promotional activities of other companies’ products.
In particular, Eisai has a solid basis for product marketing in the neurology area
achieved by Aricept*.
The addition of Eril™ to the product lineup will bring greater synergy
and enable further contributions to greater numbers of patients.
AKP will strengthen its business base in the Chinese market through a
concentration of management resources on the osteoporosis therapy
Elcitonin™ and the immunosuppressant Bredinin™,
both of which are key products in China.
The agreement announced today will enable both AKP and Eisai
to gain enhanced presence in their respective fields of focus while
heightening market recognition for Eril™, for the ultimate benefit
of the patient.
* Aricept is a registered trademark of Eisai Co., Ltd.
|
|
